Transdermal Delivery Solutions Corp   Report issue

For profit Phase 2 Phase 3
Founded: Palm Beach Gardens FL United States (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2013
NCT01894308
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Transdermal Delivery Solutions Corp

Active Ingredients

Drugs in Phase 3 Trials (1)

insulin human (humulin) (2 trials)

Drugs in Phase 2 Trials (1)

testosterone (delatestryl) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypogonadism (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2